NanGenex is committed to further progress the development programs of the DRGT Group.

DRGT has 30 candidates in its preclinical and clinical pipeline in indications such as oncology, pain, erectile dysfunction and various other therapeutics applications offering multiple collaboration and licensing opportunities.

For information about collaboration and licensing opportunities please contact us through our holding company: